ALIVUS
LIFE SCIENCES
Evolve every day

July 30, 2026

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

Ref: Scrip Code: 543322

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Name: ALIVUS

Dear Sirs,

Sub: Unaudited Financial Results for the First Quarter ended June 30, 2026

Pursuant to Regulations 30 and 33 of the SEBI (LODR), 2015, we wish to inform you that the Board at its meeting held today approved the Unaudited Financial Results for the First Quarter ended June 30, 2026.

The said meeting of the Board commenced at 4.45 p.m. and concluded at 5.50 p.m.

The copy of the said Results and Limited Review Report of the Auditor is enclosed herewith.

These are also being made available on the website of the Company at www.alivus.com

You are requested to take the same on record.

Thanking You.

Yours faithfully,
For Alivus Life Sciences Limited
(formerly Glenmark Life Sciences Limited)

ALIVUS LIFE SCIENCES LIMITED

Rudalf Corriea
Company Secretary and Compliance Officer
Encl.: As above

ALIVUS LIFE SCIENCES

Evolve every day

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2026

(₹ in Million, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Year ended
		June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
		(Unaudited)	(Refer No 7)	(Unaudited)	Audited
I	**Income**				
	Revenue from operations	6,404.14	6,891.17	6,018.46	25,518.32
	Other income	224.01	227.78	89.85	604.11
	Total income	**6,628.15**	**7,118.95**	**6,108.31**	**26,122.43**
II	**Expenses**				
	Cost of materials consumed	2,531.46	2,287.07	2,689.75	10,630.05
	Changes in inventories of finished goods and work-in-progress	18.98	421.39	14.10	35.63
	Employee benefits expense	682.45	781.22	615.77	2,724.69
	Finance costs	13.07	13.09	12.51	53.72
	Depreciation and amortisation expenses	205.85	202.00	170.64	753.57
	Other expenses	1,054.11	1,256.19	975.73	4,155.11
	Total expenses	**4,505.92**	**4,960.96**	**4,478.50**	**18,352.77**
III	**Profit before exceptional items and tax (I-II)**	**2,122.23**	**2,157.99**	**1,629.81**	**7,769.66**
IV	**Exceptional items (refer note 6)**				
	Statutory impact of new labour codes	-	-	-	256.57
V	**Profit before tax (III-IV)**	**2,122.23**	**2,157.99**	**1,629.81**	**7,513.09**
VI	**Tax expenses**				
	Current tax	502.74	510.89	389.36	1,838.92
	Deferred tax	18.73	20.49	25.10	29.34
	Total tax expenses	**521.47**	**531.38**	**414.46**	**1,868.26**
VII	**Net profit for the period / year (V-VI)**	**1,600.76**	**1,626.61**	**1,215.35**	**5,644.83**
VIII	**Other comprehensive income**				
	Items that will not be reclassified to profit or loss				
	(a) Re-measurement of the post-employment benefit obligation	4.12	17.12	(4.00)	16.47
	(b) Income tax relating to the above	(1.04)	(4.30)	0.96	(4.23)
	Total other comprehensive income / (loss), after tax	**3.08**	**12.82**	**(3.04)**	**12.24**
IX	**Total comprehensive income for the period / year (VII+VIII)**	**1,603.84**	**1,639.43**	**1,212.31**	**5,657.07**
X	Paid up equity share capital, equity shares of ₹ 2/- each	245.48	245.47	245.26	245.47
XI	Other equity excluding revaluation reserve				33,075.85
XII	**Earnings per equity share (Face value of ₹ 2/- each) (not annualised except for the year ended 31st March)**				
	(a) Basic (in ₹)	13.04	13.23	9.91	45.99
	(b) Diluted (in ₹)	13.01	13.22	9.88	45.90

See accompanying notes to the financial results

WALKER CHANDIOK & CO LLP MUMBAI CHARTERED ACCOUNTANTS

ALIVUS LIFE SCIENCES LIMITED

ALIVUS
LIFE SCIENCES
Evolve every day

Notes:

1. The above financial results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including relevant circulars issued from time to time.

2. The above financial results were reviewed and recommended by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on July 30, 2026. The results for the quarter ended June 30, 2026 have been subjected to limited review by the statutory auditors of the company, who have expressed an unmodified review conclusion on the said results.

3. The Company has identified only one segment i.e. Active Pharmaceutical Ingredient (API) as reporting segment based on the information reviewed by Chief Operating Decision Maker (CODM).

4. As at June 30, 2026, pursuant to Employee Stock Option Plan 2021, 542,531 options were outstanding, which upon exercise are convertible into equivalent number of equity share.

5. The paid-up equity share capital stands increased to Rs. 245.48 million (122,739,448 equity shares of face value Rs. 2 each) upon allotment of 3,100 equity shares of Rs. 2 each pursuant to "Employee Stock Option Scheme, 2021" during the quarter ended June 30, 2026.

6. Exceptional items for the year ended March 31, 2026 includes the incremental effect on application of new labour codes comprising gratuity amounting to Rs. 170.02 million and compensated absences amounting to Rs. 86.55 million, recognised as past service cost.

7. The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year and the unaudited year to date figures upto the third quarter of the relevant financial year.

For Alivus Life Sciences Limited
(formerly Glenmark Life Sciences Limited)

Yasir Rawjee
Managing Director & CEO
DIN: 01965174

ALIVUS LIFE SCIENCES LIMITED

WALKER CHANDIOK & Co LLP MUMBAI CHARTERED ACCOUNTANTS

Mumbai, July 30, 2026

Walker Chandiok & Co LLP

42nd Floor,
Building Commerz III, International
Business Park, Oberoi Garden City,
Off Western Express Highway,
Goregaon (East),
Mumbai-400063

T +91 22 6626 2699

Independent Auditor's Review Report on Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited)

1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) ('the Company') for the quarter ended 30 June 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

WALKER CHANDIOK & CO LLP MUMBAI CHARTERED ACCOUNTANTS

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No.: 001076N/N500013

WALKER CHANDIOK & Co LLP
MUMBAI
CHARTERED ACCOUNTANTS

Anuj Chaudhary
Partner
Membership No. 147657

UDIN: 26147657BUYAHS7451

Place: Mumbai
Date: 30 July 2026